USPTO Examiner KLINKEL KORTNEY L - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19271410Sapropterin FormulationJuly 2025March 2026Allow811YesNo
18667748POLYMERIC BIOMATERIALS DERIVED FROM PHENOLIC MONOMERS AND THEIR MEDICAL USESMay 2024March 2026Allow2221NoNo
18342395TREATMENT OF PRURIGO NODULARISJune 2023March 2025Abandon2120NoYes
18111210SMALL MOLECULES THAT TREAT OR PREVENT VIRAL INFECTIONSFebruary 2023October 2025Allow3220NoNo
18163748Sapropterin FormulationFebruary 2023March 2026Abandon3721NoNo
18008152QUINAZOLINE-DERIVED HCK INHIBITORS FOR USE IN THE TREATMENT OF MYD88 MUTATED DISEASESDecember 2022January 2026Abandon3710NoNo
18007529POLYGLYCEROL FATTY ACID ESTER COMPOSITION AND APPLICATION THEREOFDecember 2022March 2026Abandon3901NoNo
17922982PHARMACEUTICAL COMBINATION COMPRISING A BRAIN AMINOPEPTIDASE A INHIBITOR, A DIURETIC AND A BLOCKER OF THE SYSTEMIC RENIN-ANGIOTENSIN SYSTEMNovember 2022December 2025Abandon3701NoNo
17922647METHOD FOR TREATING SYMPTOMS OF VIRAL INFECTIONSNovember 2022February 2026Abandon3910NoNo
17959512BROAD SPECTRUM ANTIVIRAL AND METHODS OF USEOctober 2022July 2024Abandon2110NoNo
17915878FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONSSeptember 2022December 2025Abandon3810NoNo
17822211GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELINGAugust 2022June 2024Abandon2210NoNo
17818294TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A SEVERE INFLUENZA CONDITIONAugust 2022June 2024Abandon2210NoNo
17795747COMPOUNDS AND USES THEREOFJuly 2022March 2026Allow4320YesNo
17759546COMPOUNDS FOR USE IN THE TREATMENT OF LEUKEMIAJuly 2022January 2026Allow4220YesNo
17856781COMPOSITIONS FOR TREATING ACNEJuly 2022June 2024Abandon2410NoNo
17836620ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORJune 2022June 2024Abandon2501NoNo
17779854PROCESS FOR THE PREPARATION OF 5-CHLORO-PYRIDINE-2-CARBOXYLIC ACIDS AND CARBOXYLATES WITH 3-SULFUR CONTAINING SUBSTITUENTSMay 2022March 2026Allow4620NoYes
17736912Methods For Reducing Liver Fat and For Treating Fatty Liver DisordersMay 2022May 2024Abandon2440NoNo
17772815ROR Gamma T Inhibitors and Topical Uses ThereofApril 2022March 2026Abandon4611NoNo
17765086METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOARTHRITISMarch 2022March 2026Abandon4711NoNo
17577685PHORBOL ESTER COMPOSITIONS AND METHODS OF USE FOR TREATING OR REDUCING THE DURATION OF CYTOPENIAJanuary 2022February 2026Abandon4911NoNo
17625327PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CORONAVIRUS DISEASE-19January 2022October 2025Allow4520YesNo
17569049METHODS OF TREATING DISEASES CHARACTERISED BY VASOCONSTRICTIONJanuary 2022February 2024Abandon2510NoNo
17560469FORMULATIONS OF LIXIVAPTAN FOR THE TREATMENT OF POLYCYSTIC DISEASEDecember 2021January 2024Abandon2510NoNo
17621137EP2 ANTAGONISTDecember 2021February 2026Allow5021NoNo
17620918TRANSPLANTATION DEVICE USING CHEMICALLY CROSSLINKED ALGINIC ACIDDecember 2021January 2026Allow4921YesNo
17596827EXOSOMES FOR DISEASE TREATMENTDecember 2021February 2026Allow5011NoNo
17545487TREATMENT OF PRURIGO NODULARISDecember 2021January 2024Abandon2510NoNo
17533347Compositions and Methods for the Treatment of Prader-Willi SyndromeNovember 2021January 2024Abandon2610NoNo
17528000COMPOSITIONS AND METHODS FOR TREATING AN INFECTIONNovember 2021January 2024Abandon2610NoNo
17512531ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOFOctober 2021January 2024Abandon2610NoNo
17494824AGENTS FOR REVERSING TOXIC PROTEINOPATHIESOctober 2021December 2023Allow2610YesNo
17391023Enhanced Rodeferin Broad SpectrumAugust 2021September 2021Allow100YesNo
17310122METHOD FOR PREPARING ORYZANOL FROM ORYZANOL-CONTAINING SOAPSTOCK SERVING AS RAW MATERIALJuly 2021March 2023Abandon2020NoNo
17370675COMBINATION ANTI-CANCER PRODUCTS AND METHODSJuly 2021August 2024Abandon3721NoNo
17365602USE OF TERPENOIDS IN THE TREATMENT OR PREVENTION OF FIBROTIC DISEASESJuly 2021June 2024Abandon3620NoNo
17346602METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONSJune 2021June 2024Abandon3620NoNo
17342117Compositions of Azadirachta Indica and Methods of Treating CancerJune 2021May 2024Abandon3520NoNo
17297826HIGH-PURITY STEVIOL GLYCOSIDESMay 2021March 2026Abandon5721NoNo
17307985HETEROCYCLIC MODULATORS OF LIPID SYNTHESISMay 2021February 2024Abandon3311NoNo
17230270METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERSApril 2021July 2024Allow4040NoNo
17226814SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASESApril 2021April 2024Abandon3621NoNo
17224691METHODS OF TREATING AND/OR PREVENTING VIRAL INFECTIONS AND/OR DISEASES CAUSED BY VIRUSES IN A SUBJECT IN NEED THEREOFApril 2021February 2024Abandon3430YesYes
17274909METHOD FOR CONTROLLING PESTS OF POTATO PLANTSMarch 2021September 2025Allow5530YesNo
17253505OGA INHIBITOR COMPOUNDSDecember 2020April 2024Abandon4010NoNo
17252613NLRP MODULATORSDecember 2020May 2023Abandon2801NoNo
17251532GUANIDINIUM DERIVATIVES AS IMMUNITY-INDUCING AGENTDecember 2020May 2023Abandon2901NoNo
17114473COMPOSITIONS FOR PREVENTION OR TREATMENT OF ACUTE RADIATION SYNDROME AND OTHER RADIATION EXPOSUREDecember 2020September 2022Allow2121YesNo
17055647FORMULATIONS AND METHODS FOR THE PREVENTION OF OPIOID OVERDOSENovember 2020April 2024Abandon4110NoNo
17054614QUINOLINE COMPOUNDS AND THEIR PREPARATION AND USE AS ANTIMALARIAL AGENTSNovember 2020February 2026Abandon6041YesNo
15733748USE OF CHLOROGENIC ACID IN PREPARING DRUG FOR PREVENTING OR BLOCKING BRAIN AND/OR BONE METASTASES OF LUNG CANCEROctober 2020December 2025Abandon6040NoYes
17046633SMALL MOLECULE MODULATORS OF PAR2 AND USES THEREOFOctober 2020January 2024Allow3921YesNo
17042623TREATMENT AND PREVENTION OF ALPHA HERPES VIRUS INFECTIONSeptember 2020July 2024Abandon4640NoNo
17024149COMPOSITIONS, DEVICES, AND METHODS FOR THE TREATMENT OF OPIOID-RECEPTOR-MEDIATED CONDITIONSSeptember 2020March 2025Abandon5440YesYes
16968214RAPAMYCIN ANALOG FOR PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE CONDITIONSAugust 2020August 2023Abandon3620NoNo
16966079METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES OR CONDITIONS USING CHRNA6 ACTIVATORSJuly 2020March 2023Abandon3111NoNo
16938247COMPOSITIONS AND METHODS FOR TREATING AN INFECTIONJuly 2020July 2025Abandon6020NoYes
16963075THERAPEUTIC TARGETING OF RECEPTOR TYROSINE KINASE INHIBITOR-INDUCED ANDROGEN RECEPTOR PHOSPHORYATION IN CANCERJuly 2020July 2024Abandon4741YesNo
16919677METHODS OF TREATING HIVJuly 2020March 2024Abandon4440YesNo
16958299COMPOSITIONS FOR TREATING INFECTIVE ARTERIAL DISEASES AND RELATED CONDITIONSJune 2020May 2024Abandon4620NoYes
16910392COMPOSITION COMPRISING FARNESOL AND USE THEREOFJune 2020January 2023Abandon3121NoNo
16957490COMPOSITION FOR INHIBITING REACTIVE OXYGEN SPECIES PRODUCTIONJune 2020June 2023Abandon3621NoNo
16956740COMPOSITIONS AND METHODS FOR TREATING NEOPLASIAJune 2020June 2023Abandon3621YesNo
16902730OXYSTEROLS AND METHODS OF USE THEREOFJune 2020June 2023Abandon3621NoNo
16767121METHOD FOR PREDICTING AND MODULATING SUSCEPTIBILITY OF CANCER CELL TO PROGRAMMED CELL DEATHMay 2020July 2023Abandon3811NoNo
16763498STEROIDAL COMPOUNDS FOR TREATMENT OF MENTAL AND NEUROLOGICAL DISORDERSMay 2020April 2023Abandon3521YesNo
16652723Viral InhibitorApril 2020May 2024Abandon4950NoNo
16821365AUTOTAXIN INHIBITORS AND USES THEREOFMarch 2020June 2025Allow6060NoYes
16633242METHODS OF TREATING INFLUENZA-ASSOCIATED VIRAL PNEUMONIAJanuary 2020March 2024Abandon5020NoYes
16736095COMPOSITIONS AND METHODS FOR ENHANCING SEXUAL PLEASURE AND PERFORMANCEJanuary 2020March 2025Abandon6061YesYes
16727577COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERSDecember 2019August 2023Abandon4431NoNo
16694197WATER SOLUBLE FORMULATION FOR PHARMACEUTICAL AND NUTRACEUTICAL COMPOUNDS AND METHOD OF PREPARING THEREOFNovember 2019May 2021Abandon1721NoNo
16615485Composition for Improving Brain FunctionNovember 2019March 2023Abandon3921YesNo
16607353Method for Inhibiting Both Glycolysis and Glutamine Metabolism in Cells and Use ThereofOctober 2019December 2022Abandon3821NoNo
16584626ALTERING EXPRESSION LEVEL OF GLUTATHIONE S-TRANSFERASE GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDESeptember 2019August 2024Abandon5861YesNo
16403288Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen FumarateMay 2019January 2020Allow840YesYes
16341476COMPOSITION FOR PREVENTING OR TREATING HEPATITIS CONTAINING MONOACETYL DIACYLGLYCEROL COMPOUNDApril 2019May 2023Abandon4931NoYes
16331407COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERSMarch 2019March 2022Abandon3621NoNo
16325867USE OF BCL-XL INHIBITOR AND ONCOLYTIC VIRUS IN PREPARATION OF ANTITUMOR DRUGFebruary 2019December 2022Abandon4601NoNo
16501039Methods and compositions for the treatment of diverticulosisFebruary 2019December 2021Allow3421YesNo
16314851Use of Scavengers of Reactive Gamma-Ketoaldehydes to Extend Cell Lifespan and HealthspanJanuary 2019November 2022Allow6031NoYes
16225672CHROMOPHORE COMBINATIONS FOR BIOPHOTONIC USESDecember 2018June 2023Abandon5451YesNo
16220890Nutraceutical Compositions Comprising C60 and Cox-2 InhibitorDecember 2018September 2021Allow3351NoNo
16309026COMPOSITIONS AND METHODS FOR MODELING HEART FAILURE WITH PRESERVED EJECTION FRACTIONDecember 2018January 2023Abandon4901NoNo
16215854PESTICIDE COMPOSITION COMPRISING A TETRAZOLYLOXIME DERIVATIVE AND A FUNGICIDE OR AN INSECTICIDE ACTIVE SUBSTANCEDecember 2018August 2021Allow3211NoNo
16095224USE OF THYROID BETA-AGONISTSOctober 2018January 2022Abandon3921NoNo
16138028AGENT CONTAINING FAT (OIL), WHICH CONTAINS ONION EXTRACT, THE PRODUCTION AND USE THEREOF FOR CARING, PREVENTING OR TREATING DAMAGED SKIN TISSUE, ESPECIALLY SCARRED TISSUESeptember 2018February 2022Abandon4121NoNo
16062946PHOSPHONIC ETHYLENIC POLYMER AND COSMETIC USES THEREOFJune 2018August 2021Allow3911YesNo
15756286SOLID SOLUBLE FERRIC PYROPHOSPHATE FORMULATIONS, KITS, AND METHODS USING THE SAMEFebruary 2018June 2022Allow5241YesYes
15748880METHOD AND COMPOSITIONJanuary 2018March 2023Abandon6061YesNo
15748625METHODS OF TREATING ACNE USING NANOEMULSION COMPOSITIONSJanuary 2018April 2023Abandon6061YesNo
15746996ANTIMICROBIAL COMPOSITIONS FOR SURGICAL APPLICATIONSJanuary 2018July 2022Abandon5441NoNo
15745490THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCERJanuary 2018November 2022Abandon5841YesNo
15856853COMPOSITIONS AND METHODS COMPRISING CELECOXIB OR RELATED COMPOUNDS AND DEXTROMETHORPHANDecember 2017January 2023Abandon6041NoYes
15736550COMBINATION THERAPY USING BELINOSTAT AND PRALATREXATE TO TREAT LYMPHOMADecember 2017May 2022Allow5341YesNo
15579007METHODS OF DIAGNOSING AND TREATING CANCERDecember 2017February 2022Abandon5031NoNo
15577625METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELSNovember 2017December 2022Abandon6041YesNo
15564088METHODS AND COMPOSITIONS FOR TREATING GASTRIC ULCERSOctober 2017January 2022Allow5151YesNo
15668542NOVEL ANTI-INFLAMMATORY AGENTSAugust 2017March 2023Abandon6061NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KLINKEL, KORTNEY L.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
6
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.4%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
21
Allowed After Appeal Filing
1
(4.8%)
Not Allowed After Appeal Filing
20
(95.2%)
Filing Benefit Percentile
11.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 4.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KLINKEL, KORTNEY L - Prosecution Strategy Guide

Executive Summary

Examiner KLINKEL, KORTNEY L works in Art Unit 1627 and has examined 106 patent applications in our dataset. With an allowance rate of 40.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 44 months.

Allowance Patterns

Examiner KLINKEL, KORTNEY L's allowance rate of 40.6% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KLINKEL, KORTNEY L receive 2.71 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KLINKEL, KORTNEY L is 44 months. This places the examiner in the 14% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.0% benefit to allowance rate for applications examined by KLINKEL, KORTNEY L. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 13.4% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.1% of cases where such amendments are filed. This entry rate is in the 19% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 85.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 57.1% of appeals filed. This is in the 29% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.4% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 14.0% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.